Xavier Artignan

3.8k total citations · 1 hit paper
37 papers, 652 citations indexed

About

Xavier Artignan is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Radiation. According to data from OpenAlex, Xavier Artignan has authored 37 papers receiving a total of 652 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Pulmonary and Respiratory Medicine, 13 papers in Oncology and 9 papers in Radiation. Recurrent topics in Xavier Artignan's work include Advanced Radiotherapy Techniques (9 papers), Prostate Cancer Diagnosis and Treatment (8 papers) and Prostate Cancer Treatment and Research (7 papers). Xavier Artignan is often cited by papers focused on Advanced Radiotherapy Techniques (9 papers), Prostate Cancer Diagnosis and Treatment (8 papers) and Prostate Cancer Treatment and Research (7 papers). Xavier Artignan collaborates with scholars based in France, Belgium and United States. Xavier Artignan's co-authors include David A. Jaffray, Monique H.P. Smitsmans, Harry Bartelink, M. Bolla, J. Wolthaus, Joos V. Lebesque, Christophe Louvet, D. Gargot, Florence Castan and Nathalie Bonichon-Lamichhane and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and International Journal of Radiation Oncology*Biology*Physics.

In The Last Decade

Xavier Artignan

33 papers receiving 636 citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiotherapy in patients with locally advanced rectal cancer: long-term results of the UNICANCER-PRODIGE 23 trial

2024 57 citations Thierry Conroy, Florence Castan et al. Annals of Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Xavier Artignan France	14	273	265	214	214	198	37	652
William C. Lavely United States	10	161 0.6×	318 1.2×	121 0.6×	424 2.0×	243 1.2×	15	824
Christopher G. Willet United States	11	135 0.5×	305 1.2×	264 1.2×	248 1.2×	133 0.7×	17	552
I. Rutten Belgium	11	340 1.2×	363 1.4×	100 0.5×	132 0.6×	158 0.8×	18	850
Michael C. Tjong Canada	10	100 0.4×	234 0.9×	133 0.6×	239 1.1×	96 0.5×	36	489
Aslı Okur Germany	12	82 0.3×	197 0.7×	94 0.4×	213 1.0×	127 0.6×	21	486
I. Dell’Oca Italy	18	81 0.3×	480 1.8×	492 2.3×	447 2.1×	120 0.6×	52	910
H.P. Bagshaw United States	13	103 0.4×	210 0.8×	113 0.5×	208 1.0×	81 0.4×	48	526
Adrian Wong United States	11	294 1.1×	258 1.0×	194 0.9×	153 0.7×	325 1.6×	15	642
Vincenzo Fusco Italy	15	148 0.5×	368 1.4×	340 1.6×	309 1.4×	242 1.2×	70	848
Catherine Cheze‐Le Rest France	12	87 0.3×	234 0.9×	82 0.4×	608 2.8×	150 0.8×	21	766

Countries citing papers authored by Xavier Artignan

Since Specialization

Citations

This map shows the geographic impact of Xavier Artignan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xavier Artignan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xavier Artignan more than expected).

Fields of papers citing papers by Xavier Artignan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xavier Artignan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xavier Artignan. The network helps show where Xavier Artignan may publish in the future.

Co-authorship network of co-authors of Xavier Artignan

This figure shows the co-authorship network connecting the top 25 collaborators of Xavier Artignan. A scholar is included among the top collaborators of Xavier Artignan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xavier Artignan. Xavier Artignan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Franzoi, Maria Alice, Arlindo R. Ferreira, Antoine Lemaire, et al.. (2024). Implementation of a remote symptom monitoring pathway in oncology care: analysis of real-world experience across 33 cancer centres in France and Belgium. The Lancet Regional Health - Europe. 44. 101005–101005. 15 indexed citations

Franzoi, Maria Alice, Mario Di Palma, Thomas Grellety, et al.. (2024). The impact of self-reported social determinants of health (SDOH) on patient engagement and symptom burden across a remote patient monitoring (RPM) pathway in 42 European hospitals.. Journal of Clinical Oncology. 42(16_suppl). 1506–1506. 2 indexed citations

Conroy, Thierry, Florence Castan, Pierre-Luc Etienne, et al.. (2024). Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiotherapy in patients with locally advanced rectal cancer: long-term results of the UNICANCER-PRODIGE 23 trial. Annals of Oncology. 35(10). 873–881. 57 indexed citations breakdown →

Latorzeff, I., S. Supiot, R. de Crevoisier, et al.. (2023). Indication and perspectives of radiation therapy in the setting of de-novo metastatic prostate cancer. Cancer/Radiothérapie. 28(1). 49–55.

Ferreira, Arlindo R., Antoine Lemaire, Joseph Rodriguez, et al.. (2023). Towards improvement of oncology care through digital technology: A snapshot of Resilience remote patient monitoring (RPM) system implementation across 19 hospitals in Europe.. Journal of Clinical Oncology. 41(16_suppl). 1518–1518.

Campion, L., Brigitte Vié, G. Béra, et al.. (2018). Comprehensive Geriatric Assessment and quality of life after localized prostate cancer radiotherapy in elderly patients. PLoS ONE. 13(4). e0194173–e0194173. 26 indexed citations

Lévy, Antonin, É. Bardet, Benjamin Lacas, et al.. (2016). A phase II open-label multicenter study of gefitinib in combination with irradiation followed by chemotherapy in patients with inoperable stage III non-small cell lung cancer. Oncotarget. 8(9). 15924–15933. 13 indexed citations

Bourgeois, Hugues, Philippe Solal‐Céligny, Olivier Capitain, et al.. (2014). Assessing 2-month clinical prognosis in patients with solid tumors: Final results of PRONOPALL study.. Journal of Clinical Oncology. 32(15_suppl). 9558–9558. 1 indexed citations

Guigay, J., Frédéric Peyrade, Laurence Digue, et al.. (2014). Cetuximab Relative Dose Intensity (Rdi) in Recurrent/Metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (Scchn): First Observational Prospective Study in Unselected Patients (Direct Trial). Annals of Oncology. 25. iv344–iv344. 5 indexed citations

10.

Cipolla, B., et al.. (2012). Combination of a polyamine-free oral nutritional supplement (ONS) with docetaxel in castrate-resistant prostate cancer (CRPC) patients (pts): A phase II trial.. Journal of Clinical Oncology. 30(15_suppl). e15131–e15131. 2 indexed citations

11.

Pommier, P., Sophie Dussart, T. Girinsky, et al.. (2010). Impact of 18F-Fluoro-2-Deoxyglucose Positron Emission Tomography on Treatment Strategy and Radiotherapy Planning for Stage I–II Hodgkin Disease: A Prospective Multicenter Study. International Journal of Radiation Oncology*Biology*Physics. 79(3). 823–828. 23 indexed citations

12.

Bolla, M., Jean‐Luc Descotes, Xavier Artignan, & P. Fourneret. (2007). Adjuvant treatment to radiation: combined hormone therapy and external radiotherapy for locally advanced prostate cancer. British Journal of Urology. 100(s2). 44–47. 12 indexed citations

13.

Artignan, Xavier, et al.. (2006). Quantification des mouvements prostatiques lors de l'irradiation prostatique. Cancer/Radiothérapie. 10(6-7). 381–387. 10 indexed citations

14.

Bolla, M., P. Maingon, P. Fourneret, Xavier Artignan, & Jean‐Luc Descotes. (2005). Place de l'association de radiothérapie et d'hormonothérapie dans les cancers de la prostate. Cancer/Radiothérapie. 9(6-7). 394–398. 5 indexed citations

15.

Artignan, Xavier, et al.. (2004). Online ultrasound image guidance for radiotherapy of prostate cancer: impact of image acquisition on prostate displacement. International Journal of Radiation Oncology*Biology*Physics. 59(2). 595–601. 93 indexed citations

16.

Smitsmans, Monique H.P., J. Wolthaus, Xavier Artignan, et al.. (2004). Automatic localization of the prostate for on-line or off-line image-guided radiotherapy. International Journal of Radiation Oncology*Biology*Physics. 60(2). 623–635. 69 indexed citations

17.

Soret, M., Jocelyne Troccaz, Jean-Yves Giraud, et al.. (2000). Patient set-up using portal images: 2D/2D image registration using mutual information. Computer Aided Surgery. 5(4). 246–262. 22 indexed citations

18.

Soret, M., Jocelyne Troccaz, Jean-Yves Giraud, et al.. (2000). Patient Set-Up Using Portal Images: 2D/2D Image Registration Using Mutual Information. Computer Aided Surgery. 5(4). 246–262. 14 indexed citations

19.

Bolla, M., M. Colonna, Xavier Artignan, et al.. (1999). Pathological prognostic factors in a series of 137 stage I TNM/UICC endometrial carcinomas. Radiotherapy and Oncology. 53(3). 209–211. 3 indexed citations

20.

Bolla, M., Xavier Artignan, Emmanuel Chirpaz, Jacques Balosso, & J Descotes. (1998). Données actuelles de l'association radiothérapie-hormonothérapie dans les cancers de la prostate localisés et localement évolués. Cancer/Radiothérapie. 2(6). 783–786. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact